Cardiovascular Events Associated With SGLT-2 Inhibitors Versus Other Glucose-Lowering Drugs
Hye Won Lee(Pusan National University Hospital), Donna Tan, Matthias Saathoff(University of Manitoba), Kåre I. Birkeland(Oslo University Hospital), Josep Franch‐Nadal(Tel Aviv University), Johan Bodegård(Statistics Norway), Bendix Carstensen(Steno Diabetes Centers), Reinhard W. Holl(Deutsches Diabetes-Zentrum e.V.), Anna Norhammar, Jonathan E. Shaw(St Mary's Hospital), Su‐Yen Goh(Singapore General Hospital), Eric Wittbrodt, Avraham Karasik(Maccabi Institute for Health Services Research), Suzanne V. Arnold(Saint Luke's Health System), Shun Kohsaka(Keio University Hospital), Marit E. Jørgensen(Ilisimatusarfik), John Wilding(University of Liverpool), Filip Surmont(AstraZeneca (United Kingdom)), Hanne Løvdal Gulseth, Niklas Hammar(Karolinska Institutet), Hungta Chen(AstraZeneca (United Kingdom)), Carolyn S.P. Lam(University of Glasgow), Esther Bollow, Alex Z. Fu, Kamlesh Khunti(University of Leicester), Matthew A. Cavender, Betina T. Blak, Navdeep Tangri(Orthopaedic Innovation Centre), Marcus Thuresson(Statisticon (Sweden)), Kyle Nahrebne, Yusuke Noguchi, Luis A. Garcı́a Rodrı́guez(University of Colorado Boulder), Maro R. I. Williams
Cited by 465
Related Papers
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
|European Heart Journal|2021|13.1k
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
|New England Journal of Medicine|2018|6.3k
Empagliflozin in Heart Failure with a Preserved Ejection Fraction
|New England Journal of Medicine|2021|4.6k
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
|New England Journal of Medicine|2015|2.6k
2. Classification and Diagnosis of Diabetes:<i>Standards of Care in Diabetes—2023</i>
|Diabetes Care|2022|2.4k